137 related articles for article (PubMed ID: 31729262)
1. Potential interaction of inflammatory hyperemia and hyperphosphatemia in tumorigenesis.
Brown RB
Future Oncol; 2019 Dec; 15(34):3909-3916. PubMed ID: 31729262
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer, alcohol, and phosphate toxicity.
Brown RB; Bigelow P; Dubin JA; Neiterman E
J Appl Toxicol; 2024 Jan; 44(1):17-27. PubMed ID: 37332052
[TBL] [Abstract][Full Text] [Related]
3. In vivo evidence for an interplay of FGF23/Klotho/PTH axis on the phosphate handling in renal proximal tubules.
Ide N; Ye R; Courbebaisse M; Olauson H; Densmore MJ; Larsson TE; Hanai JI; Lanske B
Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1261-F1270. PubMed ID: 29993278
[TBL] [Abstract][Full Text] [Related]
4. Inflammation and cancer.
Singh N; Baby D; Rajguru JP; Patil PB; Thakkannavar SS; Pujari VB
Ann Afr Med; 2019; 18(3):121-126. PubMed ID: 31417011
[TBL] [Abstract][Full Text] [Related]
5. Growth-associated hyperphosphatemia in young recipients accelerates aortic allograft calcification in a rat model.
Yamauchi H; Motomura N; Chung UI; Sata M; Takai D; Saito A; Ono M; Takamoto S
J Thorac Cardiovasc Surg; 2013 Feb; 145(2):522-30. PubMed ID: 22513315
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Gut-Restricted Small-Molecule Inhibitors of Intestinal Sodium-Dependent Phosphate Transport Protein 2b (NaPi2b) for the Treatment of Hyperphosphatemia.
Maemoto M; Hirata Y; Hosoe S; Ouchi J; Narushima K; Akizawa E; Tsuji Y; Takada H; Yanagisawa A; Shuto S
J Med Chem; 2022 Feb; 65(3):1946-1960. PubMed ID: 35034442
[TBL] [Abstract][Full Text] [Related]
7. Phosphate homeostasis and the renal-gastrointestinal axis.
Marks J; Debnam ES; Unwin RJ
Am J Physiol Renal Physiol; 2010 Aug; 299(2):F285-96. PubMed ID: 20534868
[TBL] [Abstract][Full Text] [Related]
8. The fundamental role of mechanical properties in the progression of cancer disease and inflammation.
Mierke CT
Rep Prog Phys; 2014 Jul; 77(7):076602. PubMed ID: 25006689
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.
Block GA; Rosenbaum DP; Yan A; Chertow GM
J Am Soc Nephrol; 2019 Apr; 30(4):641-652. PubMed ID: 30846557
[TBL] [Abstract][Full Text] [Related]
10. Phosphate toxicity and tumorigenesis.
Brown RB; Razzaque MS
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):303-309. PubMed ID: 29684520
[TBL] [Abstract][Full Text] [Related]
11. Prevention and treatment of hyperphosphatemia in chronic kidney disease.
Vervloet MG; van Ballegooijen AJ
Kidney Int; 2018 May; 93(5):1060-1072. PubMed ID: 29580635
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin COOH-terminal hydrolase L1 deletion is associated with urinary α-klotho deficiency and perturbed phosphate homeostasis.
Boisvert NC; Holterman CE; Gutsol A; Coulombe J; Pan W; Alexander RT; Gray DA; Kennedy CR
Am J Physiol Renal Physiol; 2018 Aug; 315(2):F353-F363. PubMed ID: 29667913
[TBL] [Abstract][Full Text] [Related]
13. Oral peptide specific egg antibody to intestinal sodium-dependent phosphate co-transporter-2b is effective at altering phosphate transport in vitro and in vivo.
Bobeck EA; Hellestad EM; Sand JM; Piccione ML; Bishop JW; Helvig C; Petkovich M; Cook ME
Poult Sci; 2015 Jun; 94(6):1128-37. PubMed ID: 25825784
[TBL] [Abstract][Full Text] [Related]
14. Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders.
Sherman RA
Am J Kidney Dis; 2016 Feb; 67(2):182-6. PubMed ID: 26508681
[TBL] [Abstract][Full Text] [Related]
15. [Strategies aiming to control hyperphosphatemia in chronic kidney disease].
Ureña Torres PA
Nephrol Ther; 2017 Apr; 13 Suppl 1():S95-S101. PubMed ID: 28577750
[TBL] [Abstract][Full Text] [Related]
16. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
17. Increased inorganic phosphate induces human endothelial cell apoptosis in vitro.
Di Marco GS; Hausberg M; Hillebrand U; Rustemeyer P; Wittkowski W; Lang D; Pavenstädt H
Am J Physiol Renal Physiol; 2008 Jun; 294(6):F1381-7. PubMed ID: 18385273
[TBL] [Abstract][Full Text] [Related]
18. Spuriously high phosphate level which is promptly resolved after plasmapheresis in a patient with multiple myeloma.
Kiki I; Gundogdu M; Kaya H
Transfus Apher Sci; 2007 Oct; 37(2):157-9. PubMed ID: 18037346
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease.
Yang X; Bai Q; Li Y; Liu H; Guo H; Zhang X
JPEN J Parenter Enteral Nutr; 2018 May; 42(4):766-777. PubMed ID: 28777915
[TBL] [Abstract][Full Text] [Related]
20. [The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease].
Mukhin NA; Milovanov YS; Kozlovskaya LV; Dobrosmyslov IA; Milovanova LY
Ter Arkh; 2016; 88(4):41-45. PubMed ID: 27070162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
